Skip to main content
. 2020 Jul 18;6(5):228–240. doi: 10.1007/s40495-020-00226-5

Fig. 1.

Fig. 1

Life cycle of SARS-CoV-2 and targets for drug development for COVID-19. ACE2 angiotensin converting enzyme 2, TMPRSS2 transmembrane protease serine type 2, RdRp RNA-dependent RNA polymerase, 3CLPro 3-chymotrypsin-like protease, ARDS acute respiratory distress syndrome